Correction: Lin et al. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers 2021, 13, 3367

Min Lin¹, Claudia M Kowolik¹, Jun Xie¹, Sushma Yadav^{1

2}, Larry E Overman³, David A Horne¹

Affiliations

¹ Department of Molecular Medicine, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA.
² Department of Translational Research and Cellular Therapeutics, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA.
³ Department of Chemistry, University of California, Irvine, CA 92697-2025, USA.

Published Erratum

Min Lin et al. Cancers (Basel). 2021.

. 2021 Dec 7;13(24):6151.

doi: 10.3390/cancers13246151.

Min Lin¹, Claudia M Kowolik¹, Jun Xie¹, Sushma Yadav^{1

2}, Larry E Overman³, David A Horne¹

¹ Department of Molecular Medicine, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA.
² Department of Translational Research and Cellular Therapeutics, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA.
³ Department of Chemistry, University of California, Irvine, CA 92697-2025, USA.

Abstract

There is an omission in the Institutional Review Board Statement and Conflict of Interest statements of the paper [...].

Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma.
Lin M, Kowolik CM, Xie J, Yadav S, Overman LE, Horne DA. Lin M, et al. Cancers (Basel). 2021 Jul 5;13(13):3367. doi: 10.3390/cancers13133367. Cancers (Basel). 2021. PMID: 34282785 Free PMC article.

1. Lin M., Kowolik C.M., Xie J., Yadav S., Overman L.E., Horne D.A. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers. 2021;13:3367. doi: 10.3390/cancers13133367. - DOI - PMC - PubMed